- Home
- CMPX vs PBYI Comparison
CMPX vs PBYI Comparison
Compare CMPX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- PBYI
- Stock Information
- Founded
- CMPX 2014
- PBYI 2010
- Country
- CMPX United States
- PBYI United States
- Employees
- CMPX N/A
- PBYI N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- CMPX Health Care
- PBYI Health Care
- Exchange
- CMPX Nasdaq
- PBYI Nasdaq
- Market Cap
- CMPX 214.6M
- PBYI 153.2M
- IPO Year
- CMPX N/A
- PBYI N/A
- Fundamental
- Price
- CMPX $2.00
- PBYI $3.09
- Analyst Decision
- CMPX Strong Buy
- PBYI Strong Buy
- Analyst Count
- CMPX 4
- PBYI 1
- Target Price
- CMPX $13.75
- PBYI $7.00
- AVG Volume (30 Days)
- CMPX 1.8M
- PBYI 754.5K
- Earning Date
- CMPX 11-12-2024
- PBYI 02-27-2025
- Dividend Yield
- CMPX N/A
- PBYI N/A
- EPS Growth
- CMPX N/A
- PBYI 492.79
- EPS
- CMPX N/A
- PBYI 0.47
- Revenue
- CMPX $850,000.00
- PBYI $243,569,000.00
- Revenue This Year
- CMPX N/A
- PBYI N/A
- Revenue Next Year
- CMPX $613.39
- PBYI N/A
- P/E Ratio
- CMPX N/A
- PBYI $6.63
- Revenue Growth
- CMPX N/A
- PBYI 6.30
- 52 Week Low
- CMPX $0.77
- PBYI $2.23
- 52 Week High
- CMPX $2.68
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- CMPX 65.48
- PBYI 49.17
- Support Level
- CMPX $1.43
- PBYI $2.92
- Resistance Level
- CMPX $2.68
- PBYI $4.06
- Average True Range (ATR)
- CMPX 0.24
- PBYI 0.29
- MACD
- CMPX 0.06
- PBYI 0.01
- Stochastic Oscillator
- CMPX 46.87
- PBYI 27.07
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.